← Back to Search

Hyperpolarized Pyruvate Imaging for Cancer

Q: Am I eligible to take part in this clinical trial?

This clinical trial is admitting 109 individuals with a malignant solid tumour aged between 21 and 90 years old. Patients must afford the following prerequisites: histologically verified neoplasm (with an exclusion for those with brain lesions that have radiologic features suggestive of cancer), measurable or evaluable disease as characterized by RECIST 1.1, mass larger than 1cm in length-axis, negative serum/urine <a href="https://www.withpower.com/clinical-trials/pregnancy">pregnancy</a> test if female patient can potentially bear children according to MSKCC Standard &#x26; Guidelines; this study will only accept patients suffering from <a href="https://www.withpower.com/clinical-trials/sarcoma">sarcoma</a>, <a href="https://www.withpower.com/clinical-trials/prostate">prostate</a>, breast, brain metastatic or <a href="https://www.withpower.com/clinical-trials/pancreatic-cancer">pancreatic cancer</a>. Further alterations may

Q: Are geriatric individuals excluded from participating in this research trial?

This trial is available to patients aged 21 - 90. Additionally, there are two sub-studies open for participants younger than 18 as well as 16 studies that cater to those above 65 years of age.

Q: How many individuals can take part in this clinical experiment?

Affirmative. Clinicaltrials.gov attests that this research endeavour, which was initially posted on April 1st 2015, is actively enrolling participants. Approximately 109 individuals need to be recruited from 2 separate medical centres.

Q: Is this experiment actively seeking participants?

Affirmative. Based on the information hosted on clinicaltrials.gov, this trial is actively searching for participants to join their study. It was initiated in April 2015 and lastly updated in August 2022; they are looking to enroll 109 individuals at two different medical centres.

N/A

Recruiting

Led By Kayvan Keshari, PhD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm in the long axis and/or other tumor response criteria from an MSKCC IRB-approved clinical research protocol

Negative serum or urine pregnancy test for female patients of childbearing age and potential, from assays obtained < 2 weeks prior to study enrollment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing whether a new imaging agent can help doctors more accurately see how diseases like cancer are affecting a patient's organs.

Who is the study for?

This trial is for patients with certain cancers (sarcoma, prostate, breast, brain, metastatic or pancreatic) who can undergo MRI scans. They must not be pregnant or breastfeeding and should have a tumor that's measurable. People with severe liver or kidney issues, major illnesses like unstable heart conditions, or those who cannot tolerate an MRI due to devices like pacemakers are excluded.Check my eligibility

What is being tested?

The study tests the reliability of hyperpolarized [1-13C] pyruvate (HP) in MRI scans for cancer patients by conducting two HP-MRI scans to see if they produce consistent results each time. It also compares these images with surgical pathology to check if it offers extra details on disease metabolism.See study design

What are the potential side effects?

Since this trial focuses on imaging reproducibility using hyperpolarized Pyruvate in MRIs rather than drug effects, side effects are minimal but may include discomfort from lying still during the scan and potential reactions to the contrast agent used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer can be measured or seen on scans, with a tumor larger than 1cm.

Select...

I am not pregnant, confirmed by a recent test.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

validate HP MRI at MSKCC (are the scans able to be reproduced)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Hyperpolarized Pyruvate MRI ReproducibilityExperimental Treatment1 Intervention

This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Hyperpolarized Pyruvate

2017

Completed Phase 1

~10

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

585,513 Total Patients Enrolled

Kayvan Keshari, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

Hyperpolarized Pyruvate Clinical Trial Eligibility Overview. Trial Name: NCT02421380 — N/A

Cancer Research Study Groups: Hyperpolarized Pyruvate MRI Reproducibility

Cancer Clinical Trial 2023: Hyperpolarized Pyruvate Highlights & Side Effects. Trial Name: NCT02421380 — N/A

Hyperpolarized Pyruvate 2023 Treatment Timeline for Medical Study. Trial Name: NCT02421380 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to take part in this clinical trial?

"This clinical trial is admitting 109 individuals with a malignant solid tumour aged between 21 and 90 years old. Patients must afford the following prerequisites: histologically verified neoplasm (with an exclusion for those with brain lesions that have radiologic features suggestive of cancer), measurable or evaluable disease as characterized by RECIST 1.1, mass larger than 1cm in length-axis, negative serum/urine pregnancy test if female patient can potentially bear children according to MSKCC Standard & Guidelines; this study will only accept patients suffering from sarcoma, prostate, breast, brain metastatic or pancreatic cancer. Further alterations may"

Answered by AI

Are geriatric individuals excluded from participating in this research trial?

"This trial is available to patients aged 21 - 90. Additionally, there are two sub-studies open for participants younger than 18 as well as 16 studies that cater to those above 65 years of age."

Answered by AI

How many individuals can take part in this clinical experiment?

"Affirmative. Clinicaltrials.gov attests that this research endeavour, which was initially posted on April 1st 2015, is actively enrolling participants. Approximately 109 individuals need to be recruited from 2 separate medical centres."

Answered by AI

Is this experiment actively seeking participants?

"Affirmative. Based on the information hosted on clinicaltrials.gov, this trial is actively searching for participants to join their study. It was initiated in April 2015 and lastly updated in August 2022; they are looking to enroll 109 individuals at two different medical centres."

Answered by AI

Recent research and studies

Cell MetabolismJournal

Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1

Granlund, Kristin L., Sui-Seng Tee, Hebert A. Vargas, Serge K. Lyashchenko, Ed Reznik, Samson Fine, Vincent Laudone, et al.. 2020. “Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1”. Cell Metabolism. Elsevier BV. doi:10.1016/j.cmet.2019.08.024.

clinicaltrials.govStudy

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

2015. "Characterization of Hyperpolarized Pyruvate MRI Reproducibility". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02421380.

All > Cte